XCUR Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -165.8% compared to Exicure, Inc.'s net margin of 12.65%. Exicure, Inc.'s return on equity of -130.03% beat Electromed, Inc.'s return on equity of 18.89%.

Exicure, Inc. has a consensus price target of --, signalling upside risk potential of 68.92%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.79%. Given that Exicure, Inc. has higher upside potential than Electromed, Inc., analysts believe Exicure, Inc. is more attractive than Electromed, Inc..

Exicure, Inc. has a beta of 4.079, which suggesting that the stock is 307.926% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Exicure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exicure, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Exicure, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Exicure, Inc.'s net income of -$2.4M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Exicure, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exicure, Inc. is -- versus 3.82x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -165.8% compared to Exicure, Inc.'s net margin of -36.3%. Exicure, Inc.'s return on equity of -130.03% beat Myomo, Inc.'s return on equity of -68.35%.

Exicure, Inc. has a consensus price target of --, signalling upside risk potential of 68.92%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 436.19%. Given that Myomo, Inc. has higher upside potential than Exicure, Inc., analysts believe Myomo, Inc. is more attractive than Exicure, Inc..

Exicure, Inc. has a beta of 4.079, which suggesting that the stock is 307.926% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Exicure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exicure, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Exicure, Inc. quarterly revenues are --, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Exicure, Inc.'s net income of -$2.4M is higher than Myomo, Inc.'s net income of -$3.7M. Notably, Exicure, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exicure, Inc. is -- versus 0.92x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -165.8% compared to Exicure, Inc.'s net margin of -862.39%. Exicure, Inc.'s return on equity of -130.03% beat VolitionRX Ltd.'s return on equity of --.

Exicure, Inc. has a consensus price target of --, signalling upside risk potential of 68.92%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 759.38%. Given that VolitionRX Ltd. has higher upside potential than Exicure, Inc., analysts believe VolitionRX Ltd. is more attractive than Exicure, Inc..

Exicure, Inc. has a beta of 4.079, which suggesting that the stock is 307.926% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Exicure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exicure, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Exicure, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Exicure, Inc.'s net income of -$2.4M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Exicure, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exicure, Inc. is -- versus 17.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -165.8% compared to Exicure, Inc.'s net margin of 3.93%. Exicure, Inc.'s return on equity of -130.03% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Exicure, Inc. has a consensus price target of --, signalling upside risk potential of 68.92%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 94.81%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Exicure, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Exicure, Inc..

Exicure, Inc. has a beta of 4.079, which suggesting that the stock is 307.926% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Exicure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exicure, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Exicure, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Exicure, Inc.'s net income of -$2.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Exicure, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 75.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exicure, Inc. is -- versus 0.84x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.